Articles tagged with Blood Cancer
A pioneering blood test developed by Johns Hopkins researchers, CancerSEEK, will be developed by Thrive.EarlyDetection Corp. to detect multiple cancer types at earlier stages. The technology has received Breakthrough Device designation from the FDA and has shown high specificity and sensitivity in detecting various cancers.
A new blood test, DELFI, uses machine learning to identify abnormal DNA patterns in the bloodstream for early cancer detection. The test detected cancer DNA in 57-99% of patients with various stages of breast, colorectal, and other cancers.
A study published in JNCI has identified hnRNP K as an oncogene that may cause B-cell lymphomas. The overexpression of this tumour suppressor gene was found to promote the development of cancer, leading to poor recovery and low survival rates for patients.
A study of over 19,000 people found that women with obstructive sleep apnea are more likely to be diagnosed with cancer than men. The research, published in the European Respiratory Journal, suggests that women with severe OSA and low blood oxygen levels during sleep may be at greater risk of developing cancer.
Researchers at Karolinska Institutet have found that IL-1 inhibitors can reduce chronic inflammation in blood vessels exposed to radiation, which is linked to increased risk of cardiovascular disease. The study used an animal model and gene expression analysis to support the potential treatment.
Researchers have discovered a protein, YTHDF2, that plays a key role in acute myeloid leukaemia (AML), but not in healthy blood cells. This discovery holds promise for novel treatments with fewer side effects than current chemotherapy.
A risk model has been devised by Dana-Farber Cancer Institute researchers to classify patients with asymptomatic Waldenström macroglobulinemia into low, intermediate, or high risk of developing symptomatic disease. The model uses four biomarkers and was validated on two external cohorts with high accuracy and precision.
Researchers developed a mouse model to investigate the role of persistent CD30 signaling in blood cancer development. They found that permanent CD30 activation increases the risk of B-cell lymphoma and can trigger cancer through misdirected cellular processes.
A study has shown that dogs can detect cancer in blood samples with nearly 97 percent accuracy, using their highly evolved sense of smell. The research could lead to new, inexpensive ways to detect cancer without being invasive.
A prototype wearable device can continuously collect live cancer cells directly from a patient's blood, offering a biopsy alternative. This innovation could help doctors diagnose and treat cancer more effectively by providing better information for planning treatments.
Researchers at Tohoku University developed a new imaging technique to detect tumors in lymph nodes before they grow too large. The technique uses x-ray microcomputed tomography (micro-CT) and contrast agents to map the movement of cancer cells within the lymphatic system.
Researchers developed a new blood test that can identify individual molecules in human blood samples with minimal detection errors, including rare cancer-associated proteins like mutant p53 and PD-L1. This breakthrough enables accurate disease diagnosis and novel insights into cancer mechanisms.
Researchers developed a microfluidic device that can isolate individual cancer cells from patient blood samples using size separation. The device has high efficiency and reliability, with recovery rates of up to 93% for small-cell-lung cancer cells.
Researchers have cataloged circular RNA in multiple cancers and identified it as a potential biomarker for diagnosis and prognosis. The stable structure of circRNA makes it an ideal candidate for detecting cancer in blood or urine samples.
Researchers discover microRNAs miR-146a and miR-146b play crucial role in suppressing NF-κB activation, which leads to excessive cell cycle progression and rapid tumorigenesis. The study found differences in cancer outcomes depending on the absent microRNA, offering new insights into cancer development.
Researchers at Lund University have mapped the maturation process of natural killer cells, which play a key role in fighting cancer and infections. The study found that Notch signaling is essential for NK cell development and function, highlighting its potential as a target for immunotherapies.
Researchers at Duke University Medical Center have developed a technique to expand umbilical cord blood stem cells, which appears safe and restores blood count recovery faster than standard cord blood transplant in adults with blood cancer.
Researchers have developed a technique to isolate circulating tumor cells from blood, allowing for the analysis of protein makeup without biopsies. This could lead to more effective therapies and better patient outcomes by monitoring treatment progress remotely.
Researchers have developed a blood test that can detect and classify cancer at its earliest stages by analyzing epigenetic alterations. The approach holds promise of detecting cancer long before symptoms appear, making it easier to treat.
Researchers at Dana-Farber Cancer Institute have discovered a previously unknown molecular vulnerability in two rare, aggressive cancer types, synovial sarcoma and malignant rhabdoid tumors. The study identifies the ncBAF complex as a key player in these cancers' proliferation and growth.
Researchers are investigating the link between blood clots and pancreatic tumors, which could lead to more effective treatments for patients with pancreatic cancer. The study aims to understand how blood clots form and contribute to tumor growth, potentially leading to new therapeutic approaches.
A highly sensitive liquid biopsy test detects minute traces of cancer-specific DNA, accurately determining whether HPV+ oral cancer patients are free from cancer following radiation therapy. The test reduces the need for costly radiological studies and provides a more precise count of tumor DNA in the blood.
Researchers developed a new combination treatment that flips the switch on melanoma cells by targeting Bcl-2, MCL-1, and DRP-1 proteins. The approach killed melanoma cells and cancer stem cells in laboratory tests, offering an alternative option for patients who don't respond to current treatments.
Researchers at the University of Bradford have developed a universal blood test that can detect cancer in patients under suspicion of the disease with high accuracy. The test measures DNA damage caused by ultraviolet light and uses Artificial Intelligence to analyze thousands of cells, improving predictability beyond 93%.
Researchers developed a method to make personalized predictions of future disease outcomes for patients with myeloproliferative neoplasms. By combining genetic and clinical information, the study identified eight different genetic subgroups that link to patterns of clinical disease and patient prognosis.
A new study warns that HLH diagnoses can hide underlying malignancies, leading to delayed curative therapy for cancers. Researchers recommend using alternative diagnostic techniques to identify cancer prior to administering HLH therapy.
A team of researchers from St. Jude Children's Research Hospital and UNC Lineberger Comprehensive Cancer Center made important discoveries about the genetics of mixed phenotype acute leukemia (MPAL), a rare blood cancer with features of both myeloid and acute lymphoblastic leukemia.
A team of researchers at La Jolla Institute for Immunology has identified a previously unknown progenitor population with neutrophil characteristics, which promotes tumor growth. The discovery could serve as an early warning sign for cancer and drive new therapeutic approaches for treating neutropenia, chronic inflammation, and cancer.
Researchers at the University of Copenhagen have developed a new method to diagnose cancer at its early stages using a malaria protein. The method retrieves individual cancer cells from blood samples, catching them in greater numbers than existing methods, allowing for earlier detection and improved treatment outcomes.
Researchers found a simple combination of two blood tests can diagnose myeloma in GPs, enabling earlier diagnosis and treatment. The study analyzed over 2,700 cases and suggested integrating a system to alert clinicians to relevant symptoms or changes in blood parameters.
Researchers developed QPOP, a computational platform that identifies effective drug combinations against bortezomib-resistant MM. The platform successfully predicted dosages for combination therapies, leading to reduced tumor size and prolonged survival in mouse models.
Research found that invisible stool blood is associated with a heightened risk of death from bowel cancer, as well as circulatory, respiratory, digestive, and hormone diseases. A positive faecal occult blood test result was linked to an 8-fold increased risk of bowel cancer mortality.
A new technique detects mutations that affect large chunks of chromosomes in people with clonal hematopoiesis, a condition associated with substantially increased blood cancer risk. The study identified specific events that drive this increase in risk and suggests promising directions for future work.
A new report calls for better evaluation of side effects from modern blood cancer treatments, which have dramatically improved survival rates. The Commission proposes new approaches to reporting adverse events, including capturing chronic and cumulative effects.
A new clinical trial analysis found that combining an aromatase inhibitor with ovarian function suppression yields a 10-15% improvement in freedom from distant recurrence for high-risk younger breast cancer patients. Women at low risk saw minimal benefit, while those at intermediate risk gained a 4-5% advantage.
Researchers at Dana-Farber Cancer Institute have developed a blood test that can detect early-stage lung cancer using genome sequencing. The test, which analyzes free-floating DNA in the blood, has shown promise in detecting lung cancer with a low rate of false positives.
Scientists have engineered new anti-cancer antibodies that attract killer T cells directly to cancer cells covered with the ROR1 protein. These bi-specific antibodies can target several types of cancer and work for about five days, outlasting current approaches.
A new diagnostic test developed by researchers at UC San Diego shows promise for detecting pancreatic cancer earlier. The test uses electronic chip-based system to extract exosomes directly from blood, providing results in less than an hour. The findings have the potential to detect cancer early on without invasive surgical procedures.
Researchers found that most oncologists discuss medical marijuana with patients and nearly half recommend it, but only 30% feel knowledgeable enough to make recommendations. The study suggests a discrepancy between attitudes and practices regarding medical marijuana's utility in oncology.
Researchers have identified human-specific cancers that differ from animal counterparts, suggesting potential evolutionary origins. The study reveals cancer patterns in humans vary significantly from those of other species, highlighting the need for further investigation into the evolutionary underpinnings of cancer.
A study published in Circulation found that patients with acute thrombosis in the leg are at a three-fold higher risk of developing cancer during the first six months after the blood clot. The risk is highest for smoking-related forms of cancer, such as lung and pancreatic cancer.
The BIABooster device characterizes DNA in blood circulation with new precision and sensitivity, identifying promising signatures for cancer monitoring. It has been shown to detect DNA up to a concentration of 10 fg/μL with precisions of 20% and 3%.
Researchers at Johns Hopkins Medicine have developed a non-invasive test called UroSEEK, which uses urine samples to detect DNA mutations associated with bladder cancer. The test significantly enhances early detection for patients at risk and surveillance of those who have already been treated. When combined with cytology, the sensitiv...
Researchers at WashU Medicine used CRISPR to engineer human T cells that can attack human T cell cancers without succumbing to friendly fire. The new approach also allows for the use of therapeutic T cells from any healthy donor, eliminating the need for a matched donor or patient's own T cells.
Researchers at UT Southwestern's Simmons Cancer Center have made a historic breakthrough in CAR-T therapy for acute lymphoblastic leukemia (ALL) in children and young adults. Eighty-one percent of patients treated with CAR-T therapy went into remission, offering new hope for those previously untreatable.
Researchers developed CancerSEEK, a noninvasive blood test detecting cancer mutations and protein biomarkers in the blood. The test detected cancer with a sensitivity of 69-98% and was 99% specific.
The CancerSEEK test is a noninvasive, multianalyte test that evaluates levels of eight cancer proteins and the presence of cancer gene mutations in the blood. The test has greater than 99% specificity for cancer and can identify the location of tumors with high accuracy.
A gene enhancer cluster, BENC, plays a crucial role in regulating Myc activity and cancer growth. The discovery suggests BENC as a potential target for novel therapies against blood cancer.
Researchers discover epigenetic supersimilarity in identical twins, influencing biological characteristics and cancer risk. This phenomenon is associated with a relatively small group of genes, but many are linked to several types of cancer.
Dr. Benjamin Ebert has made significant contributions to understanding the genomic landscape of adult myelodysplastic syndromes (MDS) and its impact on both hematologic malignancies and cardiovascular disease. He is also known for his work on precision medicine and his innovative approaches to treating diseases.
Research reveals significant gaps in participation among older adults with blood cancers, underscoring the need to close the gap and increase enrollment. Most patients under 65 are over-represented, while those aged 75+ account for only 4% of trials despite being diagnosed at a higher rate.
Researchers propose a revised cancer staging approach that incorporates liquid biopsy to improve diagnosis and treatment accuracy. The new system has shown promising results in guiding cancer care, particularly in detecting early-stage cancer and tracking treatment response.
Scientists sequenced 186 bone marrow biopsies from patients with smoldering multiple myeloma, identifying mutations more frequent in high-risk patients. The study also found that cell-free DNA sequencing may help monitor patients with myeloma and its precursor conditions.
A new study demonstrates techniques to track genetic changes in multiple myeloma over time using cell-free DNA found in blood. This approach potentially provides a more representative view of the disease throughout the body than traditional bone marrow biopsies.
A study showed that treating younger patients with a combination of chemotherapy and a molecularly targeted drug significantly improves response over traditional chemotherapy alone. The therapy combination resulted in a complete response rate of 37% compared to 20% historically, with ongoing maintenance showing deepened responses.
Preliminary results from a clinical trial of nivolumab indicate effectiveness and significant side effects, prompting further trials in this group. The drug ipilimumab also produced responses in nearly one-third of patients with relapsed hematologic malignancies after an allogeneic stem cell transplant.
Researchers at MD Anderson Cancer Center presented significant advances in patient survival for various blood cancers, including multiple myeloma and mantle cell lymphoma. The studies showed promising results for new treatments, such as combination chemotherapy and targeted therapies.
Research shows adult survivors of childhood cancer were 2.6 times more likely to have hypertension than expected based on age, sex, race, and BMI. The prevalence increased over time, with 70% of survivors having hypertension by age 50.
A study found that African-American patients with multiple myeloma have increased mutations in genes BCL7A, BRWD3 and AUTS2, while white patients have more mutations in TP53 and IRF4. This suggests a different approach may be needed for targeted therapies.
Barbara Savoldo, MD, PhD, received a three-year grant to support research into an investigational CAR T-cell treatment for acute lymphoblastic leukemia with a built-in safety switch. The goal is to adapt an 'off switch' to reduce potentially lethal side effects of immunotherapy treatments.